Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Head and Neck Neoplasms × apatinib × Clear all

Phase

Phase 2 5 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 5 Stomach Neoplasms 4 Advanced Gastric Cancer 3 Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Small Cell Lung Carcinoma 1 Respiratory Tract Diseases 1 Recurrence 1 Pyloric Stenosis, Hypertrophic 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Large B-Cell, Diffuse 1 Lung Neoplasms 1 Lung Diseases 1 Locally Advanced or Metastatic Gastric Adenocarcinoma 1 Liver Neoplasms 1 Hepatic Metastasis of Colorectal Cancer 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Colorectal Cancer Recurrent 1 Biliary Tract Neoplasms 1 Advanced Triple Negative Breast Cancer 1

Interventions

pembrolizumab 22 Radiotherapy 17 Cisplatin 17 Cetuximab 11 Carboplatin 10 Nivolumab 8 Paclitaxel 7 durvalumab 6 Radiotherapy, Intensity-Modulated 5 Fluorouracil 5 Everolimus 4 Docetaxel 4 Cyclophosphamide 4 zalutumumab 3 spartalizumab 3 epacadostat 3 Ipilimumab 3 Immune Checkpoint Inhibitors 3 Gefitinib 3 Filgrastim 3 Celecoxib 3 Capecitabine 3 Amifostine 3 selpercatinib 2 fludarabine 2 cemiplimab 2 bintrafusp alfa protein, human 2 avelumab 2 Peripheral Blood Stem Cell Transplantation 2 Pemetrexed 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03654612 2018-10-18

Y-HR2017-025

China International Medical Foundation

Phase 1/2 Unknown

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡